01—Abstract
Summary
Summary of the 10-Q filed March 5, 2024. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported net revenue of $1.658 billiona for the third quarter of fiscal year 2024, a decrease of 6% compared to the prior year.
This decline was primarily driven by a 9% decrease in product revenue, influenced by customer capital expenditure pressures, particularly in the pharmaceutical and chemical/advanced materials markets. Despite the revenue dip, the company maintained a strong operational performance with net income of $348 millionb, nearly flat year-over-year. Operating cash flow significantly improved, reaching $485 million compared to $296 million in the prior year.
Agilent also continued its commitment to shareholders through dividends and has a substantial remaining authorization for share repurchases. The company is navigating a challenging macroeconomic environment, especially in China, and expects ongoing customer capital expenditure pressures. However, Agilent remains optimistic about its long-term growth prospects across its key end markets, driven by its differentiated product solutions and focus on customer experience and productivity.
02—Key points
Key Highlights
- Net revenue for the third quarter of fiscal year 2024 was $1.658 billion, a 6% decrease year-over-year.
- Product revenue decreased by 9% year-over-year, largely due to customer capital expenditure pressures in key markets.
- Net income remained strong at $348 million, a slight decrease from $352 million in the prior year.
- Operating cash flow saw a significant increase, reaching $485 million compared to $296 million in the prior year.
- The company's Life Sciences and Applied Markets segment experienced a 10% revenue decline, while Diagnostics and Genomics decreased by 6%.
- Agilent CrossLab segment showed resilience with a 6% revenue increase year-over-year.
- The company has a remaining authorization of approximately $1.524 billion for share repurchases under its 2023 repurchase program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Agilent Technologies, Inc. kept $0.21.
- Revenue$1.66B100.0%
- Cost of revenue−$750.0M45.2%
- Gross profit$908.0M54.8%
- Operating costs−$524.0M31.6%
- Operating income$384.0M23.2%
- Interest, other & tax−$36.0M2.2%
- Net income$348.0M21.0%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed March 5, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $1.66B$1.76B | −5.6% |
| Cost of Revenue | $750.00M$788.00M | −4.8% |
| Gross Profit | $908.00M$968.00M | −6.2% |
| R&D Expenses | $128.00M$123.00M | +4.1% |
| SG&A Expenses | $396.00M$419.00M | −5.5% |
| Operating Expenses | $1.27B$1.33B | −4.2% |
| Operating Income | $384.00M$426.00M | −9.9% |
| Interest Expense | $22.00M$25.00M | −12.0% |
| Net Income | $348.00M$352.00M | −1.1% |
| EPS (Basic) | $1.19$1.19 | 0.0% |
| EPS (Diluted) | $1.18$1.19 | −0.8% |
| Shares Outstanding (Basic) | 293.00M296.00M | −1.0% |
| Shares Outstanding (Diluted) | 294.00M297.00M | −1.0% |
05—Questions
Frequently Asked Questions
What was the primary driver for the year-over-year revenue decline?
The primary driver for the year-over-year revenue decline was a 9% decrease in product revenue. This was attributed to continued capital expenditure pressures faced by customers, particularly in the pharmaceutical and chemical/advanced materials markets.
How did the different business segments perform in terms of revenue?
The Life Sciences and Applied Markets segment saw a 10% decrease in revenue, and the Diagnostics and Genomics segment experienced a 6% decrease. In contrast, the Agilent CrossLab segment demonstrated growth, with revenue increasing by 6% year-over-year.
What is the company's outlook for the near future, considering the current economic conditions?
Agilent anticipates a challenging macroeconomic environment, with ongoing pressures on customer capital expenditures, especially in regions like China. The company also expects to continue facing inflationary pressures. Despite these challenges, Agilent remains optimistic about its long-term growth opportunities in its key end markets.
What is the company's capital allocation strategy regarding shareholders?
Agilent continues to return value to shareholders through dividends, paying $0.236 per common share in the quarter. Additionally, the company has a substantial remaining authorization of approximately $1.524 billion under its 2023 share repurchase program, indicating a commitment to reducing dilution and returning capital.
06—Continue